Alnylam

Categoria:

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

– Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo-Adjusted Reduction of 24-Hour Mean...

Resultados da Fase 3 dos esaios clínicos do estudo ENVIOSION do GIVLAARI ® (givosiran) publicados no Journal of Hepatology

Imagem: Journal of Hepatology P-BIO 02 de agosto de 2023 Os resultados da Fase 3...